简介:目的探讨急性大脑中动脉M2段闭塞缺血性卒中患者支架取栓治疗的初步应用效果及安全性。方法回顾性连续纳入2014年1月至2019年2月东部战区总医院卒中数据库中注册的大脑中动脉M2段闭塞的急性缺血性卒中患者19例,均接受支架取栓治疗。19例患者中,男12例,女7例;年龄48~83岁,中位年龄69(51,75)岁;合并心房颤动9例,高血压病15例,糖尿病6例,冠心病史4例,卒中史2例[此次发病前改良Rankin量表(mRS)评分均为1分],吸烟史8例;入院时美国国立卫生研究院卒中量表(NIHSS)评分5~28分,中位评分为15(11,22)分;Alberta卒中项目早期CT评分(ASPECTS)3~10分,中位评分为8(6,9)分;急性卒中Org10172治疗试验(TOAST)病因分型为大动脉粥样硬化型9例,心源性栓塞10例。分析其取栓治疗前后NIHSS评分、手术方式、血管再通、颅内出血等情况,并分析术后90d预后。改良脑梗死溶栓(mTICI)分级2b~3级为血管成功再通;mRS评分0~2分为临床预后良好,mRS评分3~6分为预后不良。结果19例患者发病至穿刺时间137~545min,中位时间为265(184,347)min,穿刺至再通时间中位数为75(58,98)min;17例患者仅使用取栓支架,2例患者联合使用球囊再通,中位取栓次数为1(1,2)次;成功再通占比为16/19,3例为mTICI分级2a级。术后24hNIHSS评分1~30分,中位评分为17(4,21)分,出院时NIHSS评分1~30分,中位评分为11(2,15)分。7例患者发生颅内出血,其中1例为症状性颅内出血,另12例未发生颅内出血。90d时随访,19例患者中死亡3例,分别为脑疝形成、糖尿病肾病导致肾功能不全、脑出血各1例;mRS评分中位数为2(1,4)分,预后良好占比为11/19(包括成功再通者10例),预后不良占比为8/19(包括成功再通者6例)。结论对急性大脑中动脉M2段闭塞缺血性卒中患者支架取栓治疗效果进行初步分析认为安全、有效,但结论有待于进一步验证。
简介:ObjectivesToevaluatetheeffectsofn-3fattyacidsonthecoronaryheartdiseasepatients.MethodsFromSeptember2007toMarch2008,60patientswithcoronaryheartdiseasewererandomlyassignedton-3fattyacidsgroup(groupN)andcontrolgroup(groupC).BothgroupsreceivedstandardcoronaryarterydiseasesecondarypreventiontreatmentandgroupNalsoreceivedeicosapentaenoicacid(EPA)1.8gplusdocosahexaenoicacid(DHA)1.2gperdayfor12weeks.Plasmatriacylglycerols,totalcholesterol,low-densitylipoproteincholesterol(LDL-C),high-densitylipoproteincholesterol(HDL-C)andbloodpressureweremeasuredbeforeandafterthestudy.ResultsPlasmatriacylglycerols,bloodpressureandLDL-ClevelwereloweringroupNaftern-3fattyacidstreatmentwhilenochangewasfoundingroupC(P<0.05).HDL-Clevelslightlyincreasedandtotalcholesterollevelslightlydecreasedaftern-3fattyacidsbutbothchangewerenotsignificant(P>0.05).ConclusionsN-3fattyacidshavebeneficialeffectsonthecoronaryarterydiseasepatients.
简介:INTRODUCTIONWiththedevelopmentofeconomyandimprovementoflifequality,theincidencesofhypertension,hyper-cholesterolemia,diabetes,obesityandsmokinghavebeenincreasedinChina,whichhasledtoasignificantincreaseinthemorbidityandmortalityofcoronaryarterydisease(CAD)~1.SinceitwasintroducedintoChinain1984,coronaryintervention(PCI)hasdevelopedrapidlyandhasbecomethemajortreatmentofCADbecauseofitsuniquecharacteristicsofminimalinvasiveand
简介:目的比较CT薄层增强扫描与3D-DSA数据源在颅内动静脉畸形(AVM)3D打印数据重组中的效果。方法前瞻性选取5例AVM患者,Spetzler-Martin分级Ⅱ级3例,Ⅲ级2例。对其中2例采用256层螺旋CT薄层增强扫描,3例采用3D-DSA旋转成像,提取检查结果的DICOM原始数据,通过Mimics14.0软件进行数字化处理,并按1∶1比例进行3D打印,获得实体模型并进行效果比较。结果基于256层螺旋CT薄层增强扫描数据源的3D打印可获取颅骨及血管的图像信息,能显示最细直径0.9mm的血管,但AVM内部细支结构难于分辨;基于3D-DSA数据的3D打印,数字减影无颅骨数据信息,但血管分支情况显示更丰富,可显示最细直径0.5mm的血管。结论应用CT薄层增强扫描或3D-DSA数据源均可获得AVM畸形团3D重组图像,而3D-DSA显示AVM畸形团空间构造效果更佳,有助于术前治疗方案的设计及相应辅助工具的开发。
简介:ObjectivesToinvestigatethechangesofβ3-adrenoceptor(β3-AR)mRNAexpressionintheratswithchronicheartfailure(CHF),andtoexploretheeffectofβblockers(βBs)onβ3mRNAexpression.MethodsThirty-fourratswererandomlydividedintoShamgroup(n=10)andheartfailuregroup(n=24).Ratmodelwasestablishedbyaorticconstriction.Thesurvivalratsinheartfailuregroupweredividedintoheartfailurecontrolgroup(HFgroup,n=6),metoprololgroup(METgroup,n=8)andcarvedilolgroup(CARgroup,n=8)threemonthsafteroperation.Metoprololtartartewasstartedorallywith12mg·kg-1·d-1,carvedilolwith6mg·kg-1·d-1,isometricsalinewasstartedinHFgroup.Afterthreemonthsofdrugtherapy,measurementofhemodynamics,indexofventricularmass,thelevelofβ3-ARmRNAexpressionwereperformed.ResultsComparedwithShamgroup,leftventricularendsystolicpressure(LVESP),andtheabsolutevaluesofmaximalrateofriseandfall(±dp/dtmax)ofleftventricularpressurewereallsignificantlydecreased(P<0.01),leftventricularenddiastolicpressure(LVEDP)wassignificantlyincreasedinHFgroup(P<0.01).ThehemodynamicparameterswereimprovedbyβBs,andcarvedilolwasmoreeffectivethanmetoprolol(P<0.01).TheindexofventricularmasswashigherinHFgroupthanMETgroup,CARgroupandShamgroup(P<0.01).βBssignificantlydecreasedtheindexofleftventricularmass(LVMI),andCarvedilolwasmoreeffectivethanmetoprolol(P<0.01).Theindexofrightventricularmass(RVMI)didnotchangeinMETgroup(P>0.05),butsignificantdecreasecouldbeseeninCARgroup(P<0.01).Thelevelofβ3-ARexpressioninleftventriclewasgreaterthanthatinrightventriclewhetherinthefailingheartorinthenon-failingheart.ComparedwithShamgroup,thelevelofβ3-ARmRNAexpressionwassignificantlyincreasedinHFgroup(P<0.01).Thelevelsofβ3-ARmRNAexpressionshowedaremarkabledecreaseinCARgroup(P<
简介:ObjectivesTostudytheeffectoflatereperfusiononcaspase-3activityofischemicmyocardiuminrabbitanditssignificance.Methods24adultrabbitswererandomlydividedinto3groups:Sham(S)withoutligationofcoronaryartery,LateReperfusion(LR)withligationfor3hoursfollowingreleasefor3hoursandPersistentIschemia(PI)withpersistentligationofcoronaryarteryfor6hours.Allanimalsweresacrificed6hoursafterthebeginningoftheexperiments.BorderregionofinfarctedmyocardiumwereincisedforanalyzingtheconcentrationofSOD,MDA,GRandtheexpressionofFADD,Caspase-3andtheapoptosisindex(AI).ResultsComparedwiththeShamgroup,LRandPIgroupexhibitedmuchhigherMDA,FADD,Caspase-3,AIandmuchlowerSOD,GR(allP<0.01).ComparedwiththePIgroup,LRgroupexhibitedhigherMDA,FADD,Caspase-3,AIandlowerSOD,GR(allP<0.05).ConclusionsLatereperfusionmarkedlyenhancedtheCaspase-3activityandthenthenumberofapoptoticcardiomyocyteinborderregionofinfractedmyocardium,whichindicatedtheexistenceoflatereperfusioninjury.ThemechanismmayinvolvethehighoxidativestressstateandexpressionofFADD.
简介:目的探讨99mTc-DTPA肾动态显像评价水化治疗预防对比剂致肾功能损伤的价值。方法选择17例接受冠状动脉造影(CAG)检查的肾功能不全代偿期患者,入选患者术前12h开始水化治疗,按照1~1.5ml/(kg.h)输入生理盐水和5%NaHCO3注射液(125ml),术后继续维持生理盐水输入12h。CAG前24h、后72h分别行99mTc-DTPA肾动态显像,测定肾小球滤过率(GFR),同时测定血清尿素氮(BUN)、血清肌酐(Scr)进行对比分析。结果17例患者术后双肾GFR、血BUN、Scr水平,与造影前比较,差异均无统计学意义(P均〉0.05)。结论99mTc-DTPA肾动态显像进一步证实了水化治疗预防对比剂导致肾功能损伤的有效性。